Related Experiment Video

Updated: Mar 19, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment

Sarah D Cramer1, Peter D Aplan2, Scott K Durum3

  • 1Cytokines and Immunity Section, Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health, Frederick, MD; Comparative Biomedical Scientist Training Program, National Institutes of Health, Bethesda, MD; Department of Veterinary Medicine, University of Maryland, College Park, MD; and.

Blood
|June 9, 2016
PubMed

Insights

Targeting interleukin-7 receptor alpha (IL-7Rα) signaling pathways shows promise for treating pediatric acute lymphoblastic leukemia (ALL). This approach may reduce chemotherapy intensity and benefit relapsed patients.

Area of Science:

  • Pediatric Oncology
  • Molecular Biology
  • Immunology

Background:

  • Advances in understanding pediatric acute lymphoblastic leukemia (ALL) pathobiology have improved survival rates.
  • A need exists for targeted therapies to reduce chemotherapy intensity and treat relapsed ALL.
  • Genetic aberrations in interleukin-7 receptor alpha (IL-7Rα) signaling pathways are common in T-cell ALL and B-cell precursor ALL.

Purpose of the Study:

  • To explore the therapeutic potential of targeting IL-7Rα signaling pathways in pediatric ALL.
  • To identify patient subsets who may benefit from IL-7Rα-targeted therapies.

Main Methods:

  • Analysis of genetic aberrations in IL-7Rα signaling pathways in pediatric ALL subtypes.
  • Review of existing and emerging therapeutic strategies targeting IL-7Rα.

Main Results:

  • IL-7Rα signaling pathways are frequently altered in both T-cell ALL and B-cell precursor ALL.
  • Targeting these pathways presents a viable strategy for novel ALL therapies.

Conclusions:

  • Targeting IL-7Rα signaling pathways offers a promising therapeutic avenue for a subset of pediatric ALL patients.
  • This approach may lead to reduced chemotherapy toxicity and improved outcomes in relapsed cases.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

896
Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

9.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K